Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab neoadjuvant and postoperative adjuvant therapy study in resectable hepatocellular carcinoma
ChiCTR1900028578Phase 3Recruiting
- Sponsor
- The First Affiliated Hospital of USTC
- Start
- Jan 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of sintilimab in hepatocellular carcinoma (HCC), sponsored by The First Affiliated Hospital of USTC. Primary endpoints: Safety follow-up and Survival time. Started Jan 2020; status: recruiting.
02
Drugs
sintilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR1900028578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900028578.